The data will be presented in an oral presentation and two poster presentations, Incyte said. The presentations include the following:

• An oral presentation of abstract No. 529: "Phase 1 Study of INCB086550, an Oral PD-L1 Inhibitor, in Immune Checkpoint-Naive Patients With Advanced Solid Tumors"
• A poster for abstract No. 545: "A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma"
• A poster for abstract No. 956: "Retifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study"

NORD announces 2021 Rare Impact Award honorees
The National Organization for Rare Disorders (NORD) announced the honorees for the 2021 Rare Impact Awards.

FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...

Lilly begins phase III trial for COVID-19 therapy
Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19.